Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
100.00%
Operating Margin
83.87%
Net Margin
95.38%
Efficiency Metrics
Revenue per Expense Ratio
6.20
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
0.00%
Income Tax Rate
0.00%
EPS
0.6900000000
Balance Sheet Analysis
Current Ratio
0.10
Cash Ratio
0.21
Working Capital
$-36.10M
Debt to Equity
0.41
Debt to Assets
26.07%
Equity Ratio
63.28%
Cash Flow Analysis
Operating Cash Flow Ratio
172.39%
Free Cash Flow Ratio
172.39%
CapEx to Revenue
0.00%
Dividends Paid
$22.51M
Stock Buybacks
No buybacks
Total Shareholder Returns
$22.51M
Cash Position Change
-21.77%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
126.34%
Net Income
124.74%
EPS
124.56%
Operating Income
122.57%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
205.97%
Operating Cash Flow
13.76%
Free Cash Flow
13.76%
Balance Sheet Health
Assets
-2.41%
Debt
-4.07%
Book Value per Share
-2.78%
Inventory
0.00%
Shareholder Returns
Dividends per Share
-6.55%
Shares Outstanding
0.02%
Long Term Trends
3Y Revenue/Share
-21.79%
5Y Revenue/Share
-49.38%
3Y Dividend/Share
-14.71%
5Y Dividend/Share
-14.71%